A Study of HB0030 Injection in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a phase Ia single-center, open-label, dose escalation study.The objectives of this
study are to evaluate the safety, toxicity, tolerability,
pharmacokinetics/pharmacodynamics(PK/PD), immunogenicity, biomarkers, and antitumor activity
of HB0030 in advanced solid tumor subjects.